11th week of 2009 patent applcation highlights part 49 |
Patent application number | Title | Published |
20090069193 | METHOD OF PROVIDING A PATTERN OF BIOLOGICAL-BINDING AREAS FOR BIOLOGICAL TESTING - The present invention provides a method of forming one or more biological-binding areas on a substrate for biological-testing. The method includes activating at least a portion of a glass-ceramic substrate comprising glass and one or more metal containing compounds. The one or more metal containing compounds have a range of diameters that are less than about 300 nanometers in diameter and are spaced an average distance of at least one-half the midpoint of the diameter range apart. The one or more metals include compounds selected from metal oxides, metal nanoparticles, metal alloys, and atomic metals. The glass-ceramic substrate is heated to a temperature near the glass transformation temperature to form one or more metal nanoparticles in one or more ceramic biological-binding areas. The glass-ceramic substrate is etched to expose one or more metal. One or more biological molecules are contacted with one or more ceramic biological-binding areas to provide one or more biological testing areas with an increased binding area as compared to un-activated areas. | 2009-03-12 |
20090069194 | COPY NUMBER VARIATION DETERMINATION, METHODS AND SYSTEMS - The present invention methods and systems for determining copy number variation of a target polynucleotide in a genome of a subject including amplification based techniques. Methods can include pre-amplification of the sample followed by distribution of sample and a plurality of reaction volumes, quantitative detection of a target polynucleotide and a reference polynucleotide, and analysis so as to determine the relative copy number of the target polynucleotide sequence in the genome of the subject. | 2009-03-12 |
20090069195 | COMPOSITIONS AND METHODS FOR ARRAY-BASED NUCLEIC ACID HYBRIDIZATION - The invention provides compositions and methods for generating a molecular profile of genomic DNA by hybridization of labeled nucleic acid representing the genomic DNA to immobilized nucleic acid probes, e.g., arrays or biochips. | 2009-03-12 |
20090069196 | Prediction of Breast Cancer Response to Chemotherapy - Method for the prediction of the response to epirubicin/cyclophosphamide-based chemotherapy of a breast cancer in a patient, from a tumour sample of said patient, comprising steps of determining the expression level of a group of marker genes consisting of (i) a first marker gene selected from the group consisting of MLPH, SPDEF, and AKR7A3; and (ii) a pair of second marker genes selected from the group of pairs consisting of (H2BFS and UBE2S), (BGN and ZBTB16), (ZBTB16 and EMP1), (LGALS8 and UBE2S) and (OLFML2B and ZBTB16); and (iii) a third marker gene selected from the group consisting of CYBA, ACP5, a gene specifically binding to Affymetrix probe set ID 210915 x at, LCK, GSTM3; classifying said sample as belonging to one of several breast cancer response classes from the expression levels determined; predicting the response of said breast cancer in said patient to chemotherapy from previously known characteristic properties of tumours of said one of several breast cancer response classes. | 2009-03-12 |
20090069197 | Parallel Loading of Arrays - The present inventions provides an apparatus and method for the parallel loading of multiple samples in a microarray containing a plurality of sub-arrays. The method makes use of a microarray containing multiple sub-arrays, a loading channel array, and a fluid handling robot or an assembly robot or machine. | 2009-03-12 |
20090069198 | Biomolecular Attachment Sites on Microelectronic Arrays and Methods Thereof - Methods of addressing a biomolecule to a selectively addressable electrode are described. A permeation layer overlying a plurality of selectively addressable electrodes is provided. The permeation layer includes a reactive group that is adapted to bond to a biomolecule and that requires activation through a chemical transformation before bonding to the biomolecule. At least one selectively addressable electrode is biased such that a pH change occurs in an overlying solution of the at least one selectively addressable electrode. The reactive group in a portion of the permeation layer above the at least one selectively addressable electrode is then chemically transformed to an activated reactive group as a result of the pH change. A biomolecule is then bound to the permeation layer overlying the at least one selectively addressable electrode through the activated reactive group. | 2009-03-12 |
20090069199 | METHOD AND DEVICE FOR OPTICAL DETECTION OF SUBSTANCES IN A LIQUID OR GASEOUS MEDIUM - The invention relates to a device for optical detection of substances in a liquid or gaseous medium, with a substrate with molecules for detecting the substances that are to be detected, wherein these molecules are immobilised at a surface of the substrate or in the substrate and wherein the substances that are to be detected can essentially be selectively bound to these molecules, wherein light waves can be coupled into the substrate and can be guided through this, and wherein the substrate is a foil element made of a transparent material in which a coupling structure for coupling the light waves is integrally formed and in which the coupled light waves can be guided. | 2009-03-12 |
20090069200 | System for Preparing Arrays of Biomolecules - Provided are systems for arrays for assaying various biomolecules and other compounds in a microtiter plate format. The wells are designed so as to contain subwells to facilitate fluid communication between subwells and to allow for efficient human or robotic manipulation of samples and assay of binding or other interactions of components within the wells. | 2009-03-12 |
20090069201 | METHOD OF CULTURING UNICELLULAR ORGANISMS - The invention provides a method of producing a culture of subterranean microorganisms, said method comprising: obtaining a sample of pressurized fluid from a subterranean reservoir; while maintaining said sample under pressure transferring it into a fermentation reactor; and incubating said sample in said reactor under elevated pressure. | 2009-03-12 |
20090069202 | Corrosion inhibition compositions and methods for using the same - Compositions and methods are described for inhibiting corrosion of corrodible metals present in contact with water in cooling water and other water storage systems. The compositions include concentrated stannous salts and agents to solubilize such salts. | 2009-03-12 |
20090069203 | Heat reversible gel-like lubricating composition, process for producing the same, and bearing lubricant and bearing system using said composition - A heat reversible gel-like lubricating composition having such properties that, in a service bulk temperature region, the composition is in a semi-solid gel form as with grease, but in a local high-temperature region such as a sliding contact site, the composition is homogeneously melted, is free from grease, i.e., the precipitation of foreign materials, exhibits excellent low frictional characteristics unrealizable by grease, and exhibits significant energy saving properties. The heat reversible gel-like lubricating composition includes a mineral oil and/or synthetic liquid lubricating base oil and a bisamide and/or a monoamide and has heat reversible gel properties. Preferably, the heat reversible gel-like lubricating composition contains a triamide and further contains, based on 100 parts by weight of the liquid lubricating base oil, 0.01 to 500 parts by weight in total of a bisamide and a monoamide and 0.05 to 10 parts by weight of a friction regulator. | 2009-03-12 |
20090069204 | LUBRICANT FOR OIL RETAINING BEARING - A lubricant for an oil retaining bearing containing 1 to 100% by mass of an ionic liquid. The lubricant has a low vapor pressure, low flammability, excellent heat resistance and ability to suppress the emanation of low volatile components and decomposed gases during use, or a lubricant for an oil retaining bearing which has antistatic property and is capable of grounding the static electricity generated by flow charging of the lubricant. | 2009-03-12 |
20090069205 | ADDITIVES AND LUBRICANT FORMULATIONS HAVING IMPROVED ANTIWEAR PROPERTIES - Lubricated surfaces, lubricant compositions for lubricating a surface, and methods for increasing antiwear properties in lubricants. The lubricated surface is provided by a lubricant composition including a base oil of lubricating viscosity, at least one metal salt of phosphorothioic acid, and an amount of at least one hydrocarbon soluble titanium compound effective to provide an increase in antiwear properties of the lubricant composition. A ratio of titanium metal to phosphorus in the antiwear agent ranges from about 0.3:1 to about 1.5:1. | 2009-03-12 |
20090069206 | LIQUID TREATMENT COMPOSITION - According to the present invention there is provided a pearlescent liquid treatment composition suitable for use as a laundry or hard surface cleaning composition comprising a rheology modifier providing a pouring viscosity at 20 sec | 2009-03-12 |
20090069207 | LIQUID TREATMENT COMPOSITION - According to the present invention there is provided a pearlescent liquid treatment composition suitable for use in laundering fabrics comprising a fabric care benefit agent selected from the group consisting of fabric softening agent, colour protection, pill reduction, anti-abrasion, anti-wrinkle agents and mixtures thereof and a pearlescent agent, said pearlescent agent having D0.99 volume particle size of less than 50 μm. | 2009-03-12 |
20090069208 | AQUEOUS DETERGENT COMPOSITIONS - This invention relates to aqueous enzyme-containing liquid detergents, preferably for use as a laundry booster compositions either as a pre-wash composition or in conjunction with a laundry detergent, with good enzyme stability. The stability of the enzymes is improved by the inclusion of a hydrogen peroxide destroying agent, preferably catalase. | 2009-03-12 |
20090069209 | NON-AQUEOUS WASHING APPARATUS AND METHOD - Methods and apparatuses for washing fabric loads without water or using water only as a co-solvent are disclosed. One method of non-aqueous clothes washing includes the steps of disposing clothing in a wash container, delivering a wash liquor to the fabric load, the wash liquor comprising a substantially non-reactive, non-aqueous, non-oleophilic, apolar working fluid and at least one washing additive, applying mechanical energy to the clothing and wash liquor for a sufficient amount of time to provide fabric cleaning and, thereafter, substantially removing the wash liquor from the fabric load. The working fluid may be selected from the group consisting of perfluorocarbons, hydrofluoroethers, fluoronated hydrocarbons and fluoroinerts. | 2009-03-12 |
20090069210 | COLOUR-PROTECTING LAUNDRY DETERGENT COMPOSITION - Detergent compositions comprising a color transfer inhibitor and optionally surfactant(s), the color transfer inhibitor comprising one or more compounds selected from the group consisting of triazine derivatives corresponding to general formulae I and II: | 2009-03-12 |
20090069211 | MOLDED DETERGENT COMPOSITION - A method for manufacturing a molded detergent composition is provided. The method includes mixing a hydrated component and a hydratable component without heating to provide a mixture, molding the mixture to provide a molded detergent composition, and solidifying the molded detergent composition as a result of movement of the water of hydration from the hydrated component to the hydratable component to provide the molded detergent composition as a solid under conditions of room temperature and atmospheric pressure. The hydratable component includes water, if present at all, at a level of less than about 2 wt. % based on the weight of the hydratable component. The hydratable component is a component which successfully competes with the hydrated component for at least a portion of the water of hydration. Solidification of the mixture takes between about 1 minute and about 15 minutes. | 2009-03-12 |
20090069212 | Fabric Treatment Composition - A heat activated fabric treatment composition comprising: a) at least 1% by weight of one or more quaternary ammonium fabric softening materials, b) at least 1% by weight of a non-ionic surfactant, such that components a) and b) comprise at least 30% by weight of the composition, c) at least 20% by weight of a fatty component selected from fatty acids having a melting point of at least 40° C., fatty alcohols having a melting point of at least 40° C. and mixtures thereof, d) from 5 to 30% by weight water. The composition is provided in a dispensing device which, in use, is attached to the internal panel of a tumble dryer. | 2009-03-12 |
20090069213 | Compositions for Improving the Health and Appearance of Skin - Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin. | 2009-03-12 |
20090069214 | Modulator of Metabolism Processes and Method of Its Receiving - A modulator of metabolic processes and method of manufacturing same is provided. The invention may have applicability in at least the fields of medicine, veterinary medicine, medical industry, and agriculture. The essence of invention is a chemically modified biopolymer with a polypeptide chain as an exogenous modulator of metabolic and energy exchange processes between a cell and environment, characterized in that it comprises chlorine atoms covalent-bonded with nitrogen atoms of polypeptide chain to the amount of 0.5 to 40% of the total mass of modified biopolymer, whereas the polypeptide chain includes methionine sulfoxide, cysteinic, α-aminomalonic and α-aminoacetoacetic acids to the amount of 1-20 acid residues per 1 mole of final product. The proposed modulator possesses large resource of free energy due to high degree of oxidation, thus ensuring catalytic activity when interacting with clue enzymes and return of particular organs and systems to normal physiological condition. | 2009-03-12 |
20090069215 | Acylated Single Chain Insulin - The invention is related to an acylated, single-chain insulin comprising the B- and the A-chain of human insulin or an analogue thereof connected by a connecting peptide, wherein a lysine residue being substituted for the natural amino acid residue in at least one of the positions B20, B21 or B22 in the human insulin B-chain is chemically modified by acylation. | 2009-03-12 |
20090069216 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 2009-03-12 |
20090069217 | Nutrient composition - Provided is a nutrient composition for promoting collagen production, which contains vitamin C, an iron preparation, and collagen as active ingredients, promotes collagen production in a living body such as skin or bone, prevents or treats skin aging or bone and joint diseases, and is an iron preparation-containing composition having stability imparted thereto. Also provided are a food or beverage, a feed, and a medicine each containing the nutrient composition incorporated therein. | 2009-03-12 |
20090069218 | PHARMACEUTICAL COMPOSITIONS COMPRISING CASEIN DERIVED PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides derived from casein and their use in the management of lactating animals, particularly to methods for decreasing the length of the dry period of a lactating livestock animal, for increasing its milk yield and milk hygiene after parturition and for improving the livestock welfare. The present invention further relates to pharmaceutical compositions comprising peptides derived from casein in the form of a sterile solution, which compositions are clear and substantially devoid of micelles. | 2009-03-12 |
20090069219 | DEUTERIUM-ENRICHED TELAVANCIN - The present application describes deuterium-enriched telavancin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069220 | DNA-BINDING POLYAMIDE DRUG CONJUGATES - A conjugate of formula: | 2009-03-12 |
20090069221 | Somatostatin Analogue Formulations - The present invention relates to pre-formulations of a low viscosity mixture containing: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one somatostatin analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The formulations are useful for generating depot composition for the controlled release of somatostatin analogues such as octreotide. Methods of treatment comprising the administration of such formulations are also provided, as are pre-filled administration devices and kits containing the formulations. | 2009-03-12 |
20090069222 | Compounds Useful as Modulators of the Proteasome Activity - The present invention relates to the use of compounds of the following general formula (I): wherein n | 2009-03-12 |
20090069223 | Method for treatment of vascular hyperpermeability - A method for the treatment of apoptotic-induced vascular hyperpermeability is disclosed herein. Administration of various compounds including intrinsic mitochondrial regulatory proteins, certain pharmaceuticals, antioxidants and endothelial growth factors alone or in combination results in elevating the threshold for apoptosis in patients with hemorrhagic shock. Elevating the threshold for apoptosis in patients with hemorrhagic shock decreases the amount of vascular hyperpermeability exhibited by the injured patient. Decreasing the amount of vascular hyperpermeability in a traumatized patient facilitates resuscitation and recovery from trauma and decreases the mortality and morbidity rate in injured patients. | 2009-03-12 |
20090069224 | Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics - Linear and cyclic peptidomimetics which bind to one or more melanocortin receptors are provided, which peptidomimetics include at least one ring-constrained amino acid surrogate of formula I: | 2009-03-12 |
20090069225 | SOMATOSTATIN ANALOGUES - The invention provides cyclo[{4-(NH | 2009-03-12 |
20090069226 | Transmucosal delivery of peptides and proteins - Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid, at least one additional absorption enhancing agent, and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions. | 2009-03-12 |
20090069227 | Use of HMGB1 to promote stem cell migration and/or proliferation - It is described a method to promote stem cell migration and/or proliferation in cell culture or in vivo comprising the step of exposing such cells to an effective amount of the HMGB1 protein or its active fragment. | 2009-03-12 |
20090069228 | Screening Method - The present invention provides compounds or their salts that promote or inhibit the activities of a protein comprising the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 1, compounds or their salts that promote or inhibit the activities of a gene for said protein, antisense polynucleotides comprising the whole or part of a base sequence complimentary or substantially complimentary to the base sequence of a polynucleotide encoding said protein or its partial peptide, antibodies to said protein, etc. These compounds or their salts, antisense nucleotides, antibodies, etc. can be used as agents for the prevention/treatment of mental disorders, prolactin-related disorders, etc. | 2009-03-12 |
20090069229 | PLANT-MADE WEST NILE VIRUS (WNV) VACCINES, VECTORS AND PLANT CODON OPTIMIZED SEQUENCES - The subject application provides various compositions of matter directed to West Nile virus (WNV) polypeptides and fragments thereof and polynucleotides, vectors and transformed host cells that encode, direct the expression of, or produce WNV polypeptides as set forth herein. Methods of using the polypeptides and polynucleotides for the production of immune responses in individuals or detecting the presence of WNV specific or neutralizing antibodies are also provided herein. | 2009-03-12 |
20090069230 | GDNF-DERIVED PEPTIDES - Compositions that include peptides derived from glial-derived neurotrophic factor (GDNF) (e.g., substantially pure polypeptides comprising a fragment of a GDNF precursor protein) and biologically active variants thereof are provided. The compositions can include one or more types of peptides and can include other substances (e.g., pharmaceutically acceptable carriers or diluents or liposomes). Also provided are methods for using the compositions for treatment of neurological disorders (e.g., motor system disorders and sensory system disorders). | 2009-03-12 |
20090069231 | COMPOSITIONS AND METHODS FOR TREATING DIABETIC EYE DISEASE - The present invention provides methods and composition for the treatment and diagnosis of disorders associated with excessive retinal vascularisation and vascular permeability, e.g., diabetic retinopathy and diabetic macular edema. | 2009-03-12 |
20090069232 | GLYCOSYLATION OF MOLECULES - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 2009-03-12 |
20090069233 | Agonist Peptides of Basic Fibroblast Growth Factor (bFGF) and the Method of Reduction of Wrinkles on Skin, Darkening of Hair and Acceleration of Wound Healing - The present invention is directed to synergistic therapies for the treatment of vitiligo. Particularly, the invention is directed to a composition for the reduction of wrinkles on skin, the acceleration of wound healing, and the darkening of hair including a peptide and an acceptable carrier. The peptide may be selected from the group consisting of the peptide of SEQ. ID 1, the peptide of SEQ. ID 2, the peptide of SEQ. ID 3, the peptide of SEQ. ID 4, the peptide of SEQ. ID 5, the peptide of SEQ. ID 6, the peptide of SEQ. ID 7, and the peptide of SEQ. ID 8. | 2009-03-12 |
20090069234 | CELL-PERMEABLE PEPTIDE INHIBITORS OF THE JNK SIGNAL TRANSDUCTION PATHWAY - The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. | 2009-03-12 |
20090069235 | IGF-1 Fusion Polypeptides and Therapeutic Uses Thereof - A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1. | 2009-03-12 |
20090069236 | PROCESS FOR THE PREPARATION OF HYPOALLERGENIC MAJOR BIRCH POLLEN ALLERGEN rBet v 1 - The invention relates to a process for the preparation of hypoallergenic major birch pollen allergens by means of one or more chromatographic purification steps using essentially unbuffered aqueous bases as eluent and subsequent neutralisation. The hypoallergenic major birch pollen allergens are distinguished by a lack of, but at least by reduced immunoglobulin E binding with simultaneous retention of therapeutically relevant T-cell stimulation. They can therefore be employed as low-side-effect therapeutic agents for specific immunotherapy. | 2009-03-12 |
20090069237 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS - The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use. | 2009-03-12 |
20090069238 | ACTIVATABLE CLOSTRIDIAL TOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 2009-03-12 |
20090069239 | Use of Iridoptin to Induce Toxicity in Insects - Improved methods and compounds to control insects, involving a biological control method to induce toxicity in targeted insects using iridoptin. The present invention induces high levels of apoptosis and inhibition of host protein synthesis in insect cells. It is the first viral toxin against non-lepidopteran insects and is distinct from existing bacterial toxins, such as | 2009-03-12 |
20090069240 | METHOD OF PREVENTING AND TREATING ENDOCRINE SYSTEM DISTURBANCES - The inventive medicinal agent for preventing and treating endocrine system disturbances appears as a powder prepared from ossified reindeer horns and contains 120 IU/g of luteinizing hormone, and 54 IU/g of follicle-stimulating hormone, 2,1 IU/g of prolactin, 203 pg/g of adrenocorticotropic hormone, 2,2 ng of somatotropic hormone, thyroidal hormones including 54 fmol/g of free thyroxin, 8 fmp/g of free triiodothyronine, 4,.5 μU/g of thyreotropic hormone, and 25 pmol/g of cortisol. | 2009-03-12 |
20090069241 | Compositions and Methods for Use of Pigment Epithelial Derived Factor (PEDF) Peptide Fragments - The invention provides PEDF peptides which retain the biological activity of full-length PEDF. Fusion proteins comprising a PEDF peptide are also provided. The invention further provides a codon-optimized PEDF coding sequence and method of expressing it in bacteria. Compositions, methods of use and kits are also provided. | 2009-03-12 |
20090069242 | THERAPEUTICALLY ACTIVE ALPHA MSH ANALOGUES - The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions. | 2009-03-12 |
20090069243 | NATRIURETIC ACTIVITIES - This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided. | 2009-03-12 |
20090069244 | Mutants of lactoferrin - The invention relates to field of biochemistry, molecular biology as well as medicinal chemistry. More in specific, the invention relates to polypeptides derived from human lactoferrin and their use in therapeutic or prophylactic treatment. The invention provides a polypeptide comprising a mutant of the amino acid sequence RRRRSVQWC (SEQ ID NO:2), which mutation comprising polypeptide has comparable antimicrobial activity against at least one micro-organism if compared to a reference polypeptide comprising the amino acid sequence RRRRSVQWC (SEQ ID NO:2). | 2009-03-12 |
20090069245 | GHRELIN/GROWTH HORMONE RELEASING PEPTIDE/GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders. | 2009-03-12 |
20090069246 | Methods for promoting hematopoietic and mesenchymal cell proliferation and differentiation - The present invention provides methods, improved cell culture medium and kits for promoting hematopoietic and mesenchymal stem and lineage-specific cell proliferation and differentiation by growth in the presence of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII AT | 2009-03-12 |
20090069247 | USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWEL DISEASE - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 2009-03-12 |
20090069248 | Substrate peptide sequences for plague plasminogen activator and uses thereof - The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes | 2009-03-12 |
20090069249 | METHODS FOR REDUCING OXIDATIVE STRESS IN A CELL WITH A SULFHYDRYL PROTECTED CLUTATHIONE PRODRUG - The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug. | 2009-03-12 |
20090069250 | Inhibitors of Histone Deacetylase - The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo. | 2009-03-12 |
20090069251 | Use Of Urokinase Inhibitors for the Treatment and/or Prevention of Neuropathological Diseases - The present invention relates to methods and compositions for the treatment and/or prevention of neuropathological and/or neurodegenerative diseases. In particular, the invention delivers novel uses of inhibitors of Urokinase-type Plasminogen activator in the treatment of amyotrophic lateral sclerosis. | 2009-03-12 |
20090069252 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF - The present invention provides C-glycoside derivatives and salts thereof, wherein B ring is bonded to A ring via —X— and A ring is directly bonded to the glucose residue, and it is usable as a Na | 2009-03-12 |
20090069253 | WHITENING COSMETIC COMPOSITION CONTAINING ARBUTIN NANOPARTICLES - The present invention provides a whitening cosmetic composition containing arbutin at a high concentration, whereby an improved whitening effect can be attained. In the arbutin-containing whitening cosmetic composition, arbutin is in the form of nanoparticles obtained through a nanoparticle-forming treatment of an aqueous arbutin dispersion. The composition preferably contains arbutin nanoparticles having a particle size of 10 to 150 nm in an amount of 1 to 15 wt. %. | 2009-03-12 |
20090069254 | AGENT FOR INHIBITING VISCERAL FAT ACCUMULATION - To reduce amounts of fat accumulated in abdominal cavity and to prevent or ameliorate visceral fat type obesity considered to be a main factor of metabolic syndrome, there is provided an agent or a food or drink, including as an active ingredient 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol, an organic solvent extract, a hot water extract, a squeezed liquid of a Liliaceae plant or a fraction thereof which contains the compound. | 2009-03-12 |
20090069255 | DEUTERIUM-ENRICHED CLARITHROMYCIN - The present application describes deuterium-enriched clarithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069256 | Enhancing protein expression - Modified polynucleotide compositions providing enhanced gene expression and methods for preparing said compositions are disclosed. Methods of using the compositions, such as in screening assays, diagnostic tools, kits, etc. and for prevention and/or treatment of diseases and disorders are also disclosed. | 2009-03-12 |
20090069257 | Method of achieving persistent Transgene expression - Non-inflammatory vector compositions are provided that are suitable for repeated transgene delivery and that result in persistent transgene expression. The compositions are non-inflammatory, the present compositions are suitable for readministration and do not induce expression-limiting immune or inflammatory responses. Thus, these compositions are useful in methods of repeated administration to achieve persistent transgene expression, and are especially suited to treating genetic, acquired and inflammation-associated conditions. | 2009-03-12 |
20090069258 | RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS, DNA ENCODING AND METHODS OF USE THEREOF - DNA encoding a recombinant antibody molecule end-specific for an amyloid-beta peptide, pharmaceutical compositions thereof, and a method for preventing or inhibiting progression of Alzheimer's Disease by introducing such a DNA molecule into brain cells to express the recombinant antibody molecule and prevent the accumulation of amyloid-beta peptides in the cerebrospinal fluid. | 2009-03-12 |
20090069259 | Treatment of neuropathic pain with zinc finger proteins - A variety of zinc finger proteins (ZFPs) and methods utilizing such proteins are provided for use in treating neuropathic pain. ZFPs that bind to a target site in genes that are aberrantly expressed in subjects having neuropathic pain are described. In addition, ZFPs that bind to a target site in genes expressed at normal levels in subjects experiencing neuropathic pain, modulation of whose expression results in decreased pain perception, are also provided. For example, genes that are over-expressed in the dorsal root ganglia (DRG) of pain patients (e.g., VR1, TRKA and/or Nav1.8) can be repressed, whereas genes that are under-expressed in the same populations can be activated. | 2009-03-12 |
20090069260 | METHOD FOR PRODUCING A NUCLEIC-ACID-CONTAINING COMPLEX PREPARATION - The present invention relates to a method of preparing a nucleic-acid-containing complex formulation which can be sterilized by filtration and administered intravenously to a human, and can retain stability of polynucleotides included in the nucleic-acid-containing complex formulation. The invention also relates to a method of preparing a nucleic-acid-containing complex formulation, comprising the following steps: mixing a solution comprising two separate single-stranded polynucleotides (for example, poly I and poly C) capable of forming a double strand and a solution comprising a cationic carrier or the ingredients thereof to form the cationic carrier, and performing a dispersion treatment on the mixture. | 2009-03-12 |
20090069261 | GENE THERAPY FOR SPINAL CORD DISORDERS - This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention provides a method to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene. The viral vector delivers the transgene to a region of the deep cerebellar nuclei region of the brain. Also provided are compositions and methods to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene to the motor cortex region of the subject's brain. | 2009-03-12 |
20090069262 | Cationic Oligonucleotides, Automated Methods for Preparing Same and Their Uses - The invention relates to oligonucleotide-oligocation molecules A | 2009-03-12 |
20090069263 | 4'-THIOARABINONUCLEOTIDE-CONTAINING OLIGONUCLEOTIDES, COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USES THEREOF - Oligonucleotides comprising one or more 4′-thioarabinonucleotides are described, as well as uses thereof for applications such as antisense- and RNAi-based gene silencing. 4′-thioarabinose-based phosphoramidite and H-phosphonate compounds are also described, as well as uses thereof for the synthesis of oligonucleotides comprising one or more 4′-thioarabinonucleotides. | 2009-03-12 |
20090069264 | TOXOPLASMA GONDII NUCLEIC ACID MOLECULES - The present invention relates to immunogenic | 2009-03-12 |
20090069265 | siRNA targeting inner centromere protein antigens (INCENP) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP. | 2009-03-12 |
20090069266 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID TRANSFER INTO CELLS - The present invention provides compositions and methods for increasing the transfer of nucleic acids into cells. In particular, the present invention provides for the use of inhibitors of HDAC6, a cytoplasmic histone deacetylase present in mammalian cells by, for example, small molecules or siRNA treatment, in increasing gene transfer and/or expression in cells in vitro and in vivo for research and gene therapy applications. | 2009-03-12 |
20090069267 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS - The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS. | 2009-03-12 |
20090069268 | NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE - This invention provides compounds, compositions and methods for treating cancer, infectious disease, an autoimmune disorder or an inflammatory condition. Therapeutic compounds useful in the methods of this invention are 5′-phosphoramidatyl, 1,5-substituted pyrimidine compounds, derivatives, analogs and pharmaceutically acceptable salts thereof | 2009-03-12 |
20090069269 | ORAL COMPOSITION CONTAINING DIFRUCTOSE ANHYDRIDE - An oral composition for increasing equol production by inner-intestinal bacteria, wherein such composition contains difructose anhydride as an active ingredient to activate the equol production function of inner-intestinal bacteria. | 2009-03-12 |
20090069270 | Methods for Diluting Water-Stabilized Antimicrobial Organosilane Compositions - The present invention relates to methods for diluting water-stable organosilane compositions comprising an organosilane, optionally having a non-hydrolyzable organic group, but having one or more hydrolyzable groups, and an acidified stabilizing solution prepared from at least one acid, and at least one cationic surfactant, preferably at least one quaternary ammonium salt (QAS), in water. The organosilane composition is diluted with a glycol ether. The resultant diluted organosilane composition may be used to antimicrobially treat a substrate. | 2009-03-12 |
20090069271 | WOOD TREATMENT - A method of introducing boron as a boron ester into timber via a non-aqueous liquid medium. The borate ester may have the formula I: (R | 2009-03-12 |
20090069272 | Composition for treating bone disorders - Disclosed is a new composition of matter, substantially enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid, methods of preparing this new composition of matter, a pharmaceutical composition comprising the new composition, and administration of the composition in methods of treating bone disorders such as osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis. | 2009-03-12 |
20090069273 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS - The invention relates to phosphorylated polyphenols, phosphorylated flavonoids, and phosphorylated pyrone analogs. Methods and compositions for the modulation of side effects of substances using such phosphorylated compounds are described. Methods and compositions are described for the modulation of blood-tissue barrier (BTB) transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide lowered side effects when phosphorylated pyrone analogs are coadministered with therapeutic agents. | 2009-03-12 |
20090069274 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 2009-03-12 |
20090069275 | LOW FLUSH NIACIN FORMULATION - The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment. | 2009-03-12 |
20090069276 | Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof - The present invention relates to a method for preventing, treating or ameliorating pulmonary disorders in a patient receiving a chemotherapeutic or radiotherapeutic agent or treatment comprising administering to the patient a pharmaceutical composition comprising an effective amount of active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound, or the mimic thereof, may be administered by HDPA so that high doses of the active vitamin D compound can be administered to an animal without inducing severe symptomatic hypercalcemia. | 2009-03-12 |
20090069277 | Compounds and compositions for treating infection - Compounds from 14 Kenyan plants, including from the root of | 2009-03-12 |
20090069278 | Hormonally-timed dermatological preparations - This invention provides a dermatological preparation to improve skin cosmesis or conditioning by using different formulations in a sequence that suits the needs of the skin at different points of the hormonal cycle. In its simplest implementation, this would be a two-phase skin treatment, such as a cosmetic, lotion or soap whose formulation changes to balance the differing states of hydration and reactivity of the skin during the early and late phases of the cycle. The formulations would be made in a way to be easily identified and delivered conveniently for use at different times of a hormonal cycle. The preparation would be packaged to permit the convenient purchase and dispensing of the different formulations in a manner that could be easily sequenced with the hormonal cycle. | 2009-03-12 |
20090069279 | INVERT EMULSIONS CONTAINING DHEA - Stable, recrystallization-resistant invert emulsions, suited, e.g., for preventing/treating the signs of chronological or actinic skin aging and for preventing/treating atrophy of the skin or mucous membranes, comprise a cosmetically/therapeutically effective amount of DHEA and/or chemical and/or biological precursor or derivative thereof, such invert emulsions also comprising a glycolic or hydroglycolic dispersed hydrophilic phase, a lipophilic continuous phase and an emulsifier having an HLB ranging from 2 to 7. | 2009-03-12 |
20090069280 | ANALOGS OF BENZOQUINONE-CONTAINING ANSAMYCINS AND METHODS OF USE THEREOF - The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog. | 2009-03-12 |
20090069281 | Ansamycin formulations and methods of use thereof - Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”). | 2009-03-12 |
20090069282 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS - The present invention relates to alkyne compounds of general formula I | 2009-03-12 |
20090069283 | Potassium Channel Inhibitors - The present invention relates to pyridine substituted ethanol compounds and derivatives thereof having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like. | 2009-03-12 |
20090069284 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives - Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. | 2009-03-12 |
20090069285 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitor Activity - 2-azetidinone derivatives and pharmaceutical compositions containing them. The compounds are useful in the treatment of hyperlipidemic conditions, atherosclerosis, Alzheimers' disease and cholesterol associated tumours. | 2009-03-12 |
20090069286 | DEUTERIUM-ENRICHED AZTREONAM - The present application describes deuterium-enriched aztreonam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2009-03-12 |
20090069287 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS - The invention relates to substituted azacycloalkaπe compounds useful in treating conditions of the Central Nervous System (CNS); a pharmaceutical composition comprising same; a method of treating such conditions and of treating conditions in which inhibition of beta-secretase is indicated. | 2009-03-12 |
20090069288 | Novel therapeutic compounds - Disclosed herein are novel compounds of Formula (I), | 2009-03-12 |
20090069289 | 6-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE AND PURINONE DERIVATIVES FOR IMMUNOSUPPRESSION - The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulae I and II: | 2009-03-12 |
20090069290 | Method for treating a demyelinating condition - Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca | 2009-03-12 |
20090069291 | Salt Forms - The present invention is directed to salts the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as compositions, preparations, and pharmaceutical uses thereof. | 2009-03-12 |
20090069292 | Liquid Formulations - The present invention is directed to liquid formulations of the pharmaceutical compound 1 1-piperazin- | 2009-03-12 |